{"id":10152,"date":"2020-12-02T21:58:19","date_gmt":"2020-12-02T12:58:19","guid":{"rendered":"http:\/\/cell.brc.riken.jp\/en\/?page_id=10152"},"modified":"2025-08-18T13:53:27","modified_gmt":"2025-08-18T04:53:27","slug":"diseaselist_2","status":"publish","type":"page","link":"http:\/\/cell.brc.riken.jp\/en\/hps\/patient_specific_ips\/diseaselist_2","title":{"rendered":"Metabolic diseases"},"content":{"rendered":"

\uff0a When you want to use some Disease-specific iPS cells, please e-mail to the following address.
\n\uff0a In relation to the information that are not described below, please e-mail to the following address.<\/p>\n

Contact us :\u00a0cellips.brc\"\"riken.jp<\/a><\/p>\n

Blue letter cells are available. You obtain the information by clicking the blue letter.
\n*iPS cells created using the Sendai virus vector are now available<\/a><\/p>\n

*Terms:
\nIn relation to all iPS cell lines, approval of institutional review board and\/or institutional ethical committee regarding the research using iPS cells is necessary.
\nIn relation to all iPS cell lines, commercial use is prohibited.
\nIn relation to the cell lines marked with \u25ce, (1) the recipient does not need to obtain an approval from the depositor, (2) there is no need of collaboration with the depositor, and (3) for-profit entities can also utilize.<\/p>\n

Update : 2020.11.27<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Name of diseases<\/th>\nPatient No.<\/th>\n*Terms<\/th>\nApproval Form<\/th>\nHPS<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/th>\nReference<\/th>\n<\/tr>\n
Metabolic diseases<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
1. lysosomal storage disease <\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Metachromatic leukodystrophy (MLD)<\/td>\n1<\/td>\n<\/td>\n<\/td>\nHPS0240*<\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Tay-Sachs’ disease(RCB0697 GM2-1TKB)<\/td>\n1<\/td>\n<\/td>\n<\/td>\nHPS0149*<\/a><\/td>\nHPS0150*<\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Niemann-Pick disease, Type C variant biochemical phenotype<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS0488<\/a><\/td>\nHPS0489<\/a><\/td>\nHPS0490<\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\nPMID: 23193063<\/a>
\n24399248<\/a><\/td>\n<\/tr>\n
Mucopolysaccharidosis (MPS)<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS0660<\/a><\/td>\nHPS0661<\/td>\nHPS0662<\/td>\nHPS0663<\/td>\nHPS0664<\/td>\nHPS0665<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Mucopolysaccharidosis (MPS)VI<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS0546<\/a><\/td>\nHPS0547<\/td>\nHPS0548<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS0549<\/a><\/td>\nHPS0550<\/td>\nHPS0551<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Sanfilippo syndrome, MPS IIIC (acetyl-CoA:heparan-\u03b1-\uff24-glucosaminide N-acetyltransferase deficiency)<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2870<\/a><\/td>\nHPS2871<\/td>\nHPS2872<\/td>\nHPS2873<\/td>\nHPS2874<\/td>\nHPS2875<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Fabry disease<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS3284<\/a><\/td>\nHPS3285<\/a> <\/td>\nHPS3286<\/a> <\/td>\nHPS3287<\/td>\nHPS3288<\/td>\nHPS3289<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Fabry disease, symptomatic heterozygate \/ unknown genetic etiology<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2108<\/a><\/td>\nHPS2109<\/a><\/td>\nHPS2110<\/a> <\/td>\nHPS2111<\/td>\nHPS2112<\/td>\nHPS2113<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Fabry disease, mutation of pseudogene<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1632<\/a><\/td>\nHPS1633<\/td>\nHPS1634<\/td>\nHPS1635<\/td>\nHPS1636<\/td>\nHPS1637<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
GM1-gangliosidosis<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1532<\/a><\/td>\nHPS1533<\/td>\nHPS1534<\/td>\nHPS1535<\/td>\nHPS1536<\/td>\nHPS1537<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2337<\/a><\/td>\nHPS2338<\/td>\nHPS2339<\/td>\nHPS2340<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Hunter syndrome, unknown genetic etiology<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2359<\/a><\/td>\nHPS2360<\/td>\nHPS2361<\/td>\nHPS2362<\/td>\nHPS2363<\/td>\nHPS2364<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Hunter syndrome, recombination of IDS preudogene<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1478<\/a><\/td>\nHPS1479<\/td>\nHPS1480<\/td>\nHPS1481<\/td>\nHPS1482<\/td>\nHPS1483<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Cystinosis<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1427<\/a><\/td>\nHPS1428<\/td>\nHPS1429<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Galactosialidosis, adult type<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1936<\/a><\/td>\nHPS1937<\/td>\nHPS1938<\/td>\nHPS1939<\/td>\nHPS1940<\/td>\nHPS1941<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Gaucher’s disease, type 1.1 \/ mutation in glucocerebrosidase<\/td>\n<\/a>1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2383<\/a><\/td>\nHPS2384<\/td>\nHPS2385<\/td>\nHPS2386<\/td>\nHPS2387<\/td>\nHPS2388<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2. Adrenoleukodystrophy (ALD)<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Adrenoleukodystrophy (ALD)<\/a><\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1090<\/a><\/td>\nHPS1091<\/a><\/td>\nHPS1092<\/a><\/td>\nHPS1093<\/td>\nHPS1094<\/td>\nHPS1095<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1096<\/a><\/td>\nHPS1097<\/a><\/td>\nHPS1098<\/a><\/td>\nHPS1099<\/td>\nHPS1100<\/td>\nHPS1101<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
3. Mitochondrial diseases<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Mitochondrial diseases<\/td>\n1<\/td>\n<\/td>\n<\/td>\nHPS0070*<\/a><\/td>\nHPS0071*<\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS0458<\/a><\/td>\nHPS0459<\/td>\nHPS0460<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\nPMID: 23193063<\/a>
\n24399248<\/a><\/td>\n<\/tr>\n
3<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS0461<\/a><\/td>\nHPS0462<\/td>\nHPS0463<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\nPMID: 23193063<\/a>
\n24399248<\/a><\/td>\n<\/tr>\n
4<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1853<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
5<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS1854<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Mitochondrial diseases, MELAS<\/td>\n<\/a>1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2864<\/a><\/td>\nHPS2865<\/td>\nHPS2866<\/td>\nHPS2867<\/td>\nHPS2868<\/td>\nHPS2869<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
4.Amyloid neuropathy<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Amyloid neuropathy, Familial type<\/td>\n1<\/td>\n<\/td>\n<\/td>\nHPS0224*<\/a><\/td>\nHPS0225*<\/td>\nHPS0226*<\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2<\/td>\n<\/td>\n<\/td>\nHPS0227*<\/a><\/td>\nHPS0228*<\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Systemic amyloidosis, hereditary amyloidosis<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2018<\/td>\nHPS2019<\/td>\nHPS2020<\/td>\nHPS2021<\/td>\nHPS2022<\/td>\nHPS2023<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Systemic amyloidosis, AL amyloidosis<\/a><\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2024<\/td>\nHPS2025<\/td>\nHPS2026<\/td>\nHPS2027<\/td>\nHPS2028<\/td>\nHPS2029<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
5.Wilson\u2019s disease<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Wilson’s disease\uff08RCB0390 NCU-F3\uff09<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS0049<\/a><\/td>\nHPS0050<\/td>\nHPS0051<\/td>\nHPS0052<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Wilson’s disease\uff08RCB0391 NCU-F4\uff09<\/td>\n2<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS0053<\/a><\/td>\nHPS0054<\/td>\nHPS0055<\/td>\nHPS0056<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Wilson’s disease\uff08RCB0395 NCU-F8\uff09<\/td>\n3<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS0045<\/a><\/td>\nHPS0046<\/td>\nHPS0047<\/td>\nHPS0048<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Wilson’s disease, unknown genetic etiology<\/td>\n1<\/a><\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2804<\/a><\/td>\nHPS2805<\/a><\/td>\nHPS2806<\/a><\/td>\nHPS2807<\/td>\nHPS2808<\/td>\nHPS2809<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
6.Phenylketonuria<\/span><\/strong><\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Phenylketonuria, Phenylalanine hydroxylase deficiency<\/a><\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2858<\/td>\nHPS2859<\/td>\nHPS2860<\/td>\nHPS2861<\/td>\nHPS2862<\/td>\nHPS2863<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
7. Ornithine transcarbamylase deficiency (OTCD)<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Ornithine transcarbamylase deficiency (OTCD) (RCB0492 OTCD1TKB)<\/a><\/td>\n1<\/td>\n<\/td>\nUnnecessary<\/td>\nHPS0087*<\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
8. Glycogen storage disease<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Glycogen storage disease, GSD type V (muscle glycogen phosphorylase deficiency)<\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS3254<\/td>\nHPS3255<\/td>\nHPS3256<\/td>\nHPS3257<\/td>\nHPS3258<\/td>\nHPS3259<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Pompe’s disease<\/td>\n1<\/td>\n<\/td>\n<\/td>\nHPS0175*<\/a><\/td>\nHPS0176*<\/a><\/td>\nHPS0177*<\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Pompe’s disease, adult type \/ unknown genetic etiology<\/a><\/td>\n1<\/td>\n\u25ce<\/td>\nUnnecessary<\/td>\nHPS2389<\/a><\/td>\nHPS2390<\/td>\nHPS2391<\/td>\nHPS2392<\/td>\nHPS2393<\/td>\nHPS2394<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
9. Glycogen storage disease <\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Glycogen storage disease, Type 1a<\/td>\n1<\/td>\n<\/td>\n<\/td>\nHPS3924*<\/td>\nHPS3925*<\/td>\nHPS3926*<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Glycogen storage disease, Type 1b<\/td>\n1<\/td>\n<\/td>\n<\/td>\nHPS0064*<\/a><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

\uff0a When you want to use some Disease-specific iPS cells, please e-mail to the following address. \uff0a In relation to the information that are not described below, please e-mail to the following address. Contact us :\u00a0cellips.brcriken.jp Blue letter cells are available. You obtain the information by clicking the blue letter. *iPS cells created using the Sendai virus vector are now available *Terms: In relation to all iPS cell lines, approval of institutional review board and\/or institutional ethical committee regarding the research using iPS cells is necessary. In relation to all iPS cell lines, commercial use is prohibited. In relation to the cell lines marked with \u25ce, (1) the recipient does not need to obtain an approval from the depositor, (2) there is no need of collaboration with the depositor, and (3) for-profit entities can also utilize. Update : 2020.11.27 Name of diseases Patient No. *Terms Approval Form HPS Reference Metabolic diseases 1. lysosomal storage disease Metachromatic leukodystrophy (MLD) 1 HPS0240* Tay-Sachs’ disease(RCB0697 GM2-1TKB) 1 HPS0149* HPS0150* Niemann-Pick disease, Type C variant biochemical phenotype 1 \u25ce Unnecessary HPS0488 HPS0489 HPS0490 PMID: 23193063 24399248 Mucopolysaccharidosis (MPS) 1 \u25ce Unnecessary HPS0660 HPS0661 HPS0662 HPS0663 HPS0664 HPS0665 Mucopolysaccharidosis (MPS)VI 1 \u25ce Unnecessary HPS0546 HPS0547 […]<\/p>\n","protected":false},"author":15,"featured_media":0,"parent":10124,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"both","_seopress_redirections_param":"","_seopress_redirections_type":301,"_seopress_analysis_target_kw":"","footnotes":"","_wp_rev_ctl_limit":""},"class_list":["post-10152","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/10152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/comments?post=10152"}],"version-history":[{"count":2,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/10152\/revisions"}],"predecessor-version":[{"id":10189,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/10152\/revisions\/10189"}],"up":[{"embeddable":true,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/10124"}],"wp:attachment":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/media?parent=10152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}